12:00 AM
 | 
May 07, 2007
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 1Q07 EPS est 1Q07 EPS actual Outcome Growth from 1Q06 5/4 cls Wk chg % chg Mcap chg 5/4 Mcap
Biogen Idec (BIIB) $0.61 $0.59 Missed by $0.02 7% $46.91 -$1.08 -2% -$369.5 $16,050.8
Revenues rose 17% to $715.9M from $611.2M in 1Q06. The Street was expecting $730M. Sales of Avonex interferon beta-1a for multiple sclerosis (MS) were up 14% to $448.8M from $393.4M in 1Q06. U.S. sales of Rituxan rituximab for rheumatoid arthritis (RA) and non-Hodgkin's lymphoma (NHL), as recorded by partner Genentech (DNA), were up 12% to $535M from $477M. BIIB posted $207M in 1Q Rituxan revenues. As previously reported by partner Elan (ELN), global sales of Tysabri natalizumab were $48M, up from $30M in 4Q06. BIIB posted $29.8M in...

Read the full 723 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >